AWS
CNTX icon

Atria Wealth Solutions’s Context Therapeutics CNTX Stock Holding History

Atria Wealth Solutions’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-24,000
Closed -$51K – 1772
2022
Q2 		$51K Buy
+24,000
New +$45K ﹤0.01% 1579

Other funds holding CNTX

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return
S
swisspartners Vaduz, Liechtenstein $78.4M AUM 9.82% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Atria Wealth Solutions's CNTX Position: Q3 2022 in Review

Atria Wealth Solutions sold out of Context Therapeutics (CNTX) in Q3 2022, closing a stake of 24,000 shares — an estimated $51K sold.

Atria Wealth Solutions first reported a position in CNTX in Q2 2022 and held it in 1 quarter. The position peaked at $51K in Q2 2022. 24 funds tracked by Wall St. Rank hold CNTX as of Q3 2022.

  • Atria Wealth Solutions reported no remaining Context Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Atria Wealth Solutions sold 24,000 Context Therapeutics shares in Q3 2022, an estimated $51K.
  • Atria Wealth Solutions first reported a position in Context Therapeutics in Q2 2022 and held it in 1 quarter.
  • Atria Wealth Solutions's Context Therapeutics position peaked at $51K in Q2 2022.
  • 24 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2022.

Based on Atria Wealth Solutions's 13F filing for Q3 2022, filed 14 Nov 2022.